EORTC Cutaneous Lymphoma Tumour Group(CLTG) Annual Meeting 2024

EORTC Cutaneous Lymphoma Tumour Group(CLTG) Annual Meeting 2024 is organized by MedConcept GmbH and will be held from Oct 09 - 11, 2024 at Beaulieu SA, Lausanne, Vaud, Switzerland.

Description:
At the core of this gathering resides a pivotal objective – to facilitate the convergence of experts, delegates, and sponsors from Europe and around the globe, all convened to deliberate upon the latest advancements in skin lymphoma as well as the common ground between malignant and benign skin inflammation’s research, diagnostics and treatment.

We aim to spark conversations that pinpoint key research areas and priorities. Plus, we’re addressing current patient care challenges and raising the bar for clinical practices. This event is a place for diverse minds to come together, collaborate, and find fresh solutions to today’s problems.

We aim to provide an all-encompassing conference where participants can present new research, exchange experiences, and engage in discussions about the latest advancements and emerging directions in the cross-disciplinary field of skin lymphoma, lymphoproliferative disorders, skin cancer, and both malignant and benign inflammation.

Conference Focus:
The conference will present sessions covering all aspects of cutaneous lymphomas

The CLTG Annual Meeting has evolved into the largest and most comprehensive conference globally, dedicated to the specific field where skin cancer meets inflammation – namely cutaneous lymphoma. International experts will present new data from clinical and preclinical studies, along with insights from clinical trials. Discussions will span the latest advancements in fundamental science, the establishment of high-priority research and development goals, addressing current challenges in patient care, and enhancing the treatment and management of skin lymphomas and their inflammatory counterparts.

Keynote and selected speakers will deliver overview presentations on scientific developments poised to play a pivotal role in this field in the near future. By the end of this conference, participants will be thoroughly updated in this specialized and complex field.

• Pathophysiology, Genomics and Epigenomics, Molecular targets
• Immunology, Host response, animal models, microenvironment
• Translational research, diagnostic and prognostic markers
• Pathology
• Epidemiology
• PROCLIPI research
• New treatments, clinical trials, topical and systemic therapies, combination of treatments, therapeutic strategies
• Quality of life and patient reported outcomes